Who are SEVABERTINIB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): placebo matching lapatinib, epirubicin - cyclophosphamide / docetaxel + lapatinib, Lapatinib+Capecitabine, lapatinib (GW572016).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sevabertinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

SEVABERTINIB — Competitive Intelligence Brief

SEVABERTINIB (SEVABERTINIB) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed HER2, EGFR Small molecule Live · refreshed every 30 min

Target snapshot

SEVABERTINIB (SEVABERTINIB). Sevabertinib inhibits HER2 and EGFR phosphorylation, blocking downstream signaling and cancer cell proliferation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SEVABERTINIB TARGET	SEVABERTINIB		marketed		HER2, EGFR
placebo matching lapatinib	placebo matching lapatinib	GlaxoSmithKline	marketed	HER2/EGFR tyrosine kinase inhibitor	HER2, EGFR
epirubicin - cyclophosphamide / docetaxel + lapatinib	epirubicin - cyclophosphamide / docetaxel + lapatinib	GBG Forschungs GmbH	phase 3	anthracycline antibiotic, alkylating agent, taxane, tyrosine kinase inhibitor	topoisomerase II, DNA, microtubules, HER2, EGFR
Lapatinib+Capecitabine	Lapatinib+Capecitabine	Tianjin Hemay Pharmaceutical Co., Ltd	phase 3	Tyrosine kinase inhibitor + fluoropyrimidine chemotherapy	HER2, EGFR (lapatinib); thymidylate synthase (capecitabine)
lapatinib (GW572016)	lapatinib (GW572016)	GlaxoSmithKline	phase 3	HER2/EGFR tyrosine kinase inhibitor	HER2, EGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SEVABERTINIB — Competitive Intelligence Brief. https://druglandscape.com/ci/sevabertinib. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab